-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Hepatitis -X- _ O
B -X- _ O
virus -X- _ O
( -X- _ O
HBV -X- _ O
) -X- _ O
infection -X- _ O
is -X- _ O
a -X- _ O
major -X- _ O
health -X- _ O
concern -X- _ O
with -X- _ O
more -X- _ O
than -X- _ O
two -X- _ O
billion -X- _ O
individuals -X- _ O
currently -X- _ O
infected -X- _ O
worldwide. -X- _ O
Because -X- _ O
of -X- _ O
the -X- _ O
limited -X- _ O
effectiveness -X- _ O
of -X- _ O
existing -X- _ O
vaccines -X- _ O
and -X- _ O
drugs -X- _ O
, -X- _ O
development -X- _ O
of -X- _ O
novel -X- _ O
antiviral -X- _ O
strategies -X- _ O
is -X- _ O
urgently -X- _ O
needed. -X- _ O
Heat -X- _ O
stress -X- _ O
cognate -X- _ O
70 -X- _ O
( -X- _ O
Hsc70 -X- _ O
) -X- _ O
is -X- _ O
an -X- _ O
ATP-binding -X- _ O
protein -X- _ O
of -X- _ O
the -X- _ O
heat -X- _ O
stress -X- _ O
protein -X- _ O
70 -X- _ O
family. -X- _ O
Hsc70 -X- _ O
has -X- _ O
been -X- _ O
found -X- _ O
to -X- _ O
be -X- _ O
required -X- _ O
for -X- _ O
HBV -X- _ O
DNA -X- _ O
replication. -X- _ O
Here -X- _ O
we -X- _ O
report -X- _ O
, -X- _ O
for -X- _ O
the -X- _ O
first -X- _ O
time -X- _ O
, -X- _ O
that -X- _ O
combined -X- _ B-Intervention
siRNAs -X- _ I-Intervention
targeting -X- _ I-Intervention
viral -X- _ I-Intervention
gene -X- _ I-Intervention
and -X- _ I-Intervention
siHsc70 -X- _ I-Intervention
are -X- _ O
highly -X- _ O
effective -X- _ O
in -X- _ O
suppressing -X- _ O
ongoing -X- _ O
HBV -X- _ B-Patient
expression -X- _ I-Patient
and -X- _ I-Patient
replication. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
We -X- _ O
constructed -X- _ O
two -X- _ O
plasmids -X- _ O
( -X- _ O
S1 -X- _ O
and -X- _ O
S2 -X- _ O
) -X- _ O
expressing -X- _ O
short -X- _ O
hairpin -X- _ O
RNAs -X- _ O
( -X- _ O
shRNAs -X- _ O
) -X- _ O
targeting -X- _ O
surface -X- _ O
open -X- _ O
reading -X- _ O
frame -X- _ O
of -X- _ O
HBV -X- _ O
( -X- _ O
HBVS -X- _ O
) -X- _ O
and -X- _ O
one -X- _ O
plasmid -X- _ O
expressing -X- _ O
shRNA -X- _ O
targeting -X- _ O
Hsc70 -X- _ O
( -X- _ O
siHsc70 -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
we -X- _ O
used -X- _ O
the -X- _ O
EGFP-specific -X- _ O
siRNA -X- _ O
plasmid -X- _ O
( -X- _ O
siEGFP -X- _ O
) -X- _ O
as -X- _ O
we -X- _ O
had -X- _ O
previously -X- _ O
described. -X- _ O
First -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
the -X- _ O
gene-silencing -X- _ O
efficacy -X- _ O
of -X- _ O
both -X- _ O
shRNAs -X- _ O
using -X- _ O
an -X- _ O
enhanced -X- _ O
green -X- _ O
fluorescent -X- _ O
protein -X- _ O
( -X- _ O
EGFP -X- _ O
) -X- _ O
reporter -X- _ O
system -X- _ O
and -X- _ O
flow -X- _ O
cytometry -X- _ O
in -X- _ O
HEK293 -X- _ O
and -X- _ O
T98G -X- _ O
cells. -X- _ O
Then -X- _ O
, -X- _ O
the -X- _ O
antiviral -X- _ O
potencies -X- _ O
of -X- _ O
HBV-specific -X- _ B-Intervention
siRNA -X- _ I-Intervention
( -X- _ I-Intervention
siHBV -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ I-Intervention
combination -X- _ I-Intervention
with -X- _ I-Intervention
siHsc70 -X- _ I-Intervention
in -X- _ O
HepG2.2.15 -X- _ O
cells -X- _ O
were -X- _ O
investigated. -X- _ O
Moreover -X- _ O
, -X- _ O
type -X- _ O
I -X- _ O
IFN -X- _ O
and -X- _ O
TNF- -X- _ O
α -X- _ O
induction -X- _ O
were -X- _ O
measured -X- _ O
by -X- _ O
quantitative -X- _ O
real-time -X- _ O
PCR -X- _ O
and -X- _ O
ELISA. -X- _ O
RESULTS -X- _ O
: -X- _ O
Cotransfection -X- _ B-Outcome
of -X- _ I-Outcome
either -X- _ I-Outcome
S1 -X- _ I-Outcome
or -X- _ I-Outcome
S2 -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
EGFP -X- _ I-Outcome
plasmid -X- _ I-Outcome
produced -X- _ I-Outcome
an -X- _ I-Outcome
80 -X- _ I-Outcome
% -X- _ I-Outcome
–90 -X- _ I-Outcome
% -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
EGFP -X- _ I-Outcome
signal -X- _ I-Outcome
relative -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
control. -X- _ I-Outcome
This -X- _ I-Outcome
combinational -X- _ I-Outcome
RNAi -X- _ I-Outcome
effectively -X- _ I-Outcome
and -X- _ I-Outcome
specifically -X- _ I-Outcome
inhibited -X- _ I-Outcome
HBV -X- _ I-Outcome
protein -X- _ I-Outcome
, -X- _ I-Outcome
mRNA -X- _ I-Outcome
and -X- _ I-Outcome
HBV -X- _ I-Outcome
DNA -X- _ I-Outcome
, -X- _ I-Outcome
resulting -X- _ I-Outcome
in -X- _ I-Outcome
up -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
3.36 -X- _ I-Outcome
log -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
) -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
HBV -X- _ I-Outcome
load -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
HepG2.2.15 -X- _ I-Outcome
cell -X- _ I-Outcome
culture -X- _ I-Outcome
supernatants. -X- _ I-Outcome
The -X- _ I-Outcome
combined -X- _ I-Outcome
siRNAs -X- _ I-Outcome
were -X- _ I-Outcome
more -X- _ I-Outcome
potent -X- _ I-Outcome
than -X- _ I-Outcome
siHBV -X- _ I-Outcome
or -X- _ I-Outcome
siHsc70 -X- _ I-Outcome
used -X- _ I-Outcome
separately -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
this -X- _ I-Outcome
approach -X- _ I-Outcome
can -X- _ I-Outcome
enhance -X- _ I-Outcome
potency -X- _ I-Outcome
in -X- _ I-Outcome
suppressing -X- _ I-Outcome
ongoing -X- _ I-Outcome
viral -X- _ I-Outcome
gene -X- _ I-Outcome
expression -X- _ I-Outcome
and -X- _ I-Outcome
replication -X- _ I-Outcome
in -X- _ I-Outcome
HepG2.2.15 -X- _ I-Outcome
cells -X- _ I-Outcome
while -X- _ I-Outcome
forestalling -X- _ I-Outcome
escape -X- _ I-Outcome
by -X- _ I-Outcome
mutant -X- _ I-Outcome
HBV. -X- _ I-Outcome
The -X- _ I-Outcome
antiviral -X- _ I-Outcome
synergy -X- _ I-Outcome
of -X- _ I-Outcome
siHBV -X- _ I-Outcome
used -X- _ I-Outcome
in -X- _ I-Outcome
combination -X- _ I-Outcome
with -X- _ I-Outcome
siHsc70 -X- _ I-Outcome
produced -X- _ I-Outcome
no -X- _ I-Outcome
cytotoxicity -X- _ I-Outcome
and -X- _ I-Outcome
induced -X- _ I-Outcome
no -X- _ I-Outcome
production -X- _ I-Outcome
of -X- _ I-Outcome
IFN-α -X- _ I-Outcome
, -X- _ I-Outcome
IFN-β -X- _ I-Outcome
and -X- _ I-Outcome
TNF-α -X- _ I-Outcome
in -X- _ I-Outcome
transfected -X- _ I-Outcome
cells. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Our -X- _ O
combinational -X- _ O
RNAi -X- _ O
was -X- _ O
sequence-specific -X- _ O
, -X- _ O
effective -X- _ O
against -X- _ O
wild-type -X- _ O
and -X- _ O
mutant -X- _ O
drug-resistant -X- _ O
HBV -X- _ O
strains -X- _ O
, -X- _ O
without -X- _ O
triggering -X- _ O
interferon -X- _ O
response -X- _ O
or -X- _ O
producing -X- _ O
any -X- _ O
side -X- _ O
effects. -X- _ O
These -X- _ O
findings -X- _ O
indicate -X- _ O
that -X- _ O
combinational -X- _ O
RNAi -X- _ O
has -X- _ O
tremendous -X- _ O
promise -X- _ O
for -X- _ O
developing -X- _ O
innovative -X- _ O
therapy -X- _ O
against -X- _ O
viral -X- _ O
infection -X- _ O
. -X- _ O

